Compare TNL & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNL | IRON |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 3.0B |
| IPO Year | 2006 | 2020 |
| Metric | TNL | IRON |
|---|---|---|
| Price | $73.08 | $66.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $77.75 | ★ $99.54 |
| AVG Volume (30 Days) | 626.7K | ★ 943.0K |
| Earning Date | 05-21-2026 | 05-29-2026 |
| Dividend Yield | ★ 3.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.44 | N/A |
| Revenue | ★ $4,021,000,000.00 | N/A |
| Revenue This Year | $4.73 | N/A |
| Revenue Next Year | $3.32 | $215.03 |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | ★ 4.06 | N/A |
| 52 Week Low | $37.77 | $30.82 |
| 52 Week High | $81.00 | $99.50 |
| Indicator | TNL | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | 43.58 |
| Support Level | $70.31 | $57.45 |
| Resistance Level | $74.82 | $82.70 |
| Average True Range (ATR) | 2.54 | 6.10 |
| MACD | -0.01 | 0.27 |
| Stochastic Oscillator | 26.19 | 73.52 |
Travel+Leisure Co is a membership and leisure travel company. It provides hospitality services and travel products. The company operates in the segments of Vacation Ownership, which is the key revenue-driving segment, develops, markets and sells vacation ownership interests (VOIs) to individual consumers, provides consumer financing in connection with the sale of VOIs, and provides property management services at resorts, and Travel and Membership which operates a variety of travel businesses, including two vacation exchange brands, Vacation Ownership and Travel and Membership The majority of the revenue is earned from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.